Brian Di Donato
Equibles does not estimate personal net worth.
About Brian Di Donato
Earlier roles on record: CFO at Immunocore Holdings plc (IMCR) until December 31, 2024. Immunocore Holdings plc reported in an 8-K filed August 29, 2024 that Brian Di Donato resigned as Executive Vice President, Chief Financial Officer and Head of Strategy and principal financial officer, effective December 31, 2024. The same filing states: “Mr. Di Donato’s resignation was not because of any disagreement with the Company on any matter relating to the Company’s financial statements, internal controls, operations, policies or practices, including accounting principles and practices.” The proxy statement of Immunocore Holdings plc reports total compensation of $3,439,339 for Brian Di Donato in fiscal 2024, including a base salary of $464,333. Disclosed compensation is on record for 2 fiscal years. Brian Di Donato has spoken on 5 earnings calls across 1 company, most recently for Immunocore Holdings plc on August 8, 2024. The companies whose calls Brian Di Donato spoke on are classified in the Healthcare sector.
“On August 28, 2024, Mr. Brian Di Donato notified Immunocore Holdings plc (the "Company") of his decision to resign as Executive Vice President, Chief Financial Officer and Head of Strategy and principal financial officer of the Company, effective December 31, 2024, to pursue another opportunity.”
“Mr. Di Donato’s resignation was not because of any disagreement with the Company on any matter relating to the Company’s financial statements, internal controls, operations, policies or practices, including accounting principles and practices.”
Brian Di Donato on recent calls
“We are pleased to share with you an update on Immunocore through the first half of 2024. We've achieved excellent commercial results while advancing our T cell engager platform in three therapeutic areas.”
“Earlier today, we released our financial results for the fourth quarter and year-end of 2023. Please refer to the press release and our latest SEC filing on Form 10-K for our full financial results.”
“Earlier today, we released our financial results for the second quarter ending June 30. I invite you to review the release and our SEC filings for more details.”
“Today, we will focus on the financial highlights in the fourth quarter and year-end 2022, and provide some insights into 2023. Please refer to the press release we issued this morning and our SEC filing on Form 20-F later today for our full financial results.”
“Today, we'll focus on the highlights for the second quarter that you see on Slide 8. Please refer to the press release we issued this morning for our full financial results.”
Affiliation history
-
Start not stated–2024-12-31
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Immunocore Holdings plc (IMCR) | Former Chief Financial Officer | $464,333 | $3,439,339 |
| 2023 | Immunocore Holdings plc (IMCR) | Former Chief Financial Officer | $436,000 | $3,354,443 |
Recent activity
-
Executive change Resigned: Executive Vice President, Chief Financial Officer and Head of Strategy and principal financial officer
“Mr. Di Donato’s resignation was not because of any disagreement with the Company on any matter relating to the Company’s financial statements, internal controls, operations, policies or practices, including accounting principles and practices.”
Immunocore Holdings plc (IMCR) -
-
-
-
-